0001209191-23-051895.txt : 20231004 0001209191-23-051895.hdr.sgml : 20231004 20231004160722 ACCESSION NUMBER: 0001209191-23-051895 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231002 FILED AS OF DATE: 20231004 DATE AS OF CHANGE: 20231004 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wassil Jim CENTRAL INDEX KEY: 0001813798 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39323 FILM NUMBER: 231307958 MAIL ADDRESS: STREET 1: C/O VAXCYTE, INC. STREET 2: 353 HATCH DRIVE CITY: FOSTER CITY STATE: CA ZIP: 94404 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vaxcyte, Inc. CENTRAL INDEX KEY: 0001649094 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 464233385 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 650-837-0111 MAIL ADDRESS: STREET 1: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 FORMER COMPANY: FORMER CONFORMED NAME: SutroVax, Inc. DATE OF NAME CHANGE: 20150724 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-10-02 0 0001649094 Vaxcyte, Inc. PCVX 0001813798 Wassil Jim C/O VAXCYTE, INC. 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070 0 1 0 0 Chief Operating Officer 1 Common Stock 2023-10-02 4 M 0 3000 2.42 A 173935 D Common Stock 2023-10-02 4 S 0 1542 49.69 D 172393 D Common Stock 2023-10-02 4 S 0 608 50.74 D 171785 D Common Stock 2023-10-02 4 S 0 850 51.56 D 170935 D Stock Option (right to buy) 2.42 2023-10-02 4 M 0 3000 0.00 D 2029-12-16 Common Stock 3000 107555 D The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. The price reported is a weighted-average price. The shares were sold at prices ranging from $49.19 to $50.075. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. The shares were sold at prices ranging from $50.31 to $51.13. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. The shares were sold at prices ranging from $51.39 to $51.875. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Jim Wassil, by /s/ Ron A. Metzger, Attorney-in-Fact 2023-10-04